Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis
Experimental and Clinical Endocrinology & Diabetes · 01.06.2024 · 132 (06) · 316-327
DOI: 10.1055/a-2303-8558 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.06.2024. Verfasst von Gilson Dorneles und 4 weiteren Autor:innen. Beteiligte Einrichtung: Responsabilidade Social. Hospital Moinhos de Vento. Porto Alegre/Brazil. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Overweight. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Ministério da Saúde.
Abstract (Originalsprache)
Background
To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide treatment in overweight or obese patients without type 2 diabetes.
Methods
Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023. Risk of bias was assessed with RoB 2.0, and certainty of evidence (CoE) with GRADE. A random-effects meta-analysis was conducted.
Results
Ten publications, with 22.155 patients, were included. Semaglutide decreased relative body weight (MD: −11.80; 95%CI: −13.53 to −10.07; CoE: High), absolute body weight (MD: −11.58; 95%CI: −13.25 to −9.90; CoE: High) and BMI (MD: −4.15; 95%CI: −4.85 to −3.45; CoE: High). Semaglutide also increased the proportion of patients who achieved 5%, 10%, and 15% of weight loss ([weight loss≥5%: RR 2.29, 95% CI: 1.88 to 2.80; CoE: High]; [weight loss≥10%: RR 4.54, 95% CI: 3.45 to 5.98; CoE: High]; [weight loss≥15%: RR 8.29, 95%CI: 5.54 to 12.39; CoE: High]). Semaglutide leads to small risk to adverse events (RR: 1.03; 95%CI: 1 to 1.06; CoE: High), no difference in the serious adverse events (RR: 1.07; 95%CI: 0.70 to 1.62; CoE: Low), but increases in the risk to discontinued treatment (RR: 2.03; 95%CI: 1.87 to 2.20; CoE: High) and gastrointestinal adverse events (RR: 3.26; 95%CI: 1.99 to 5.34; CoE: Moderate).
Conclusion
This up-to-date systematic review highlights that once-weekly semaglutide treatment resulted in clinically important weight loss, becoming a promising adjuvant therapy for obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Responsabilidade Social. Hospital Moinhos de Vento. Porto Alegre/Brazil.
- Núcleo de Avaliação de Tecnologias em Saúde. Hospital Universitário da Universidade da Grande Dourados. Dourados/Brazil.
- Núcleo de Avaliação de Tecnologias em Saúde - Hospital Universitário da Universidade Federal de São Carlos. São Carlos/Brazil.
- Centro de Informação Sobre Medicamentos. Secretaria de Saúde do Estado da Bahia. Salvador/Brazil.
- Instituto Capixaba de Ensino, Pesquisa e Inovação em Saúde (ICEPi), Vitória, ES, Brazil.
Förderung
- Ministério da Saúde
Zitieren
APA
Dorneles, G., Algeri, E., Lauterbach, G., Pereira, M., & Fernandes, B. (2024). Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis. Experimental and Clinical Endocrinology & Diabetes, 132(06), 316-327. https://doi.org/10.1055/a-2303-8558
Vancouver
Dorneles G, Algeri E, Lauterbach G, Pereira M, Fernandes B. Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis. Experimental and Clinical Endocrinology & Diabetes. 2024;132(06):316-327. doi:10.1055/a-2303-8558
BibTeX
@article{Dorneles2024,
author = {Dorneles, Gilson and Algeri, Ellen and Lauterbach, Gerhard and Pereira, Marcelo and Fernandes, Brigida},
title = {Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2024},
volume = {132},
number = {06},
pages = {316--327},
doi = {10.1055/a-2303-8558}
}
EUVIMED